<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02645682</url>
  </required_header>
  <id_info>
    <org_study_id>HC-I-H 1503</org_study_id>
    <nct_id>NCT02645682</nct_id>
  </id_info>
  <brief_title>The Effects of Anti-infective Central Venous Catheter on Catheter-related Infection in Critically Patients</brief_title>
  <official_title>The Effects of Anti-infective Central Venous Catheter(CVC) on Catheter-related Bloodstream Infection(CRBSI) in Critical Care Patients: a Multiple-center, Randomized, Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>West China Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of anti-infective central venous
      catheter(Certofix®Protect) on reducing catheter-related bloodstream infection in critically
      ill patients in China, and the relationship between catheter-related bloodstream infection
      and catheter-related thrombosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>catheter-related bloodstream infection</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>number of participants with catheter-related bloodstream infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>catheter-related thrombosis</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>number of participants with catheter-related thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1818</enrollment>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>anti-infection CVC (Certofix®protect)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal CVC (Certofix®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>anti-infection CVC</intervention_name>
    <arm_group_label>anti-infection CVC (Certofix®protect)</arm_group_label>
    <other_name>Certofix®protect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>normal CVC</intervention_name>
    <arm_group_label>normal CVC (Certofix®)</arm_group_label>
    <other_name>Certofix®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients in intensive care unit (ICU)（age ≥ 18 years）

          -  needs double lumen CVC more than 5 days

          -  Signed informed consent

        Exclusion Criteria:

          -  thrombosis in target and/or contralateral vein

          -  pregnancy or lactating women

          -  unlikely to survive for more than 1 month

          -  bad prognosis

          -  suspected catheter-related infection

          -  replacement CVC in original site through guide wire

          -  severe burn

          -  situation that is not suitable for CVC, including allergic to CVC material, thrombosis
             in target vein, infection of puncture site, coagulation disorder, abnormal anatomy

          -  already in this study

          -  participated in other studies within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Kang, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bin Du, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Kang, Doctor</last_name>
    <phone>(+86)189-8060-1566</phone>
    <email>kangyan_hx@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yao Chen, Doctor</last_name>
    <phone>(+86)153-0808-8233</phone>
    <email>314351895@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Du, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Kang, Doctor</last_name>
      <phone>(+86)189-8060-1566</phone>
      <email>kangyan_hx@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yao Chen, Doctor</last_name>
      <phone>(+86)153-0808-8233</phone>
      <email>314351895@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Minming Wu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://braunoviny.bbraun.cz/clanky/polyhexanide-anti-infective-coating-of-central-venous/</url>
  </link>
  <reference>
    <citation>O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, Lipsett PA, Masur H, Mermel LA, Pearson ML, Raad II, Randolph AG, Rupp ME, Saint S; Healthcare Infection Control Practices Advisory Committee. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control. 2011 May;39(4 Suppl 1):S1-34. doi: 10.1016/j.ajic.2011.01.003.</citation>
    <PMID>21511081</PMID>
  </reference>
  <reference>
    <citation>Cicalini S, Palmieri F, Petrosillo N. Clinical review: new technologies for prevention of intravascular catheter-related infections. Crit Care. 2004 Jun;8(3):157-62. Epub 2003 Sep 29. Review.</citation>
    <PMID>15153233</PMID>
  </reference>
  <reference>
    <citation>Saint S, Veenstra DL, Lipsky BA. The clinical and economic consequences of nosocomial central venous catheter-related infection: are antimicrobial catheters useful? Infect Control Hosp Epidemiol. 2000 Jun;21(6):375-80. Review.</citation>
    <PMID>10879567</PMID>
  </reference>
  <reference>
    <citation>中华医学会重症医学分会。血管内导管相关感染的预防与治疗指南。中国实用外科杂志2008; 28: 413-21</citation>
  </reference>
  <reference>
    <citation>Rupp ME. Central venous catheters coated or impregnated with antimicrobial agents effectively prevent microbial colonisation and catheter-related bloodstream infections. Evid Based Med. 2014 Apr;19(2):56. doi: 10.1136/eb-2013-101471. Epub 2013 Sep 5.</citation>
    <PMID>24009330</PMID>
  </reference>
  <reference>
    <citation>Halton KA, Cook DA, Whitby M, Paterson DL, Graves N. Cost effectiveness of antimicrobial catheters in the intensive care unit: addressing uncertainty in the decision. Crit Care. 2009;13(2):R35. doi: 10.1186/cc7744. Epub 2009 Mar 11.</citation>
    <PMID>19284570</PMID>
  </reference>
  <reference>
    <citation>Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Ann Intern Med. 1997 Aug 15;127(4):257-66.</citation>
    <PMID>9265424</PMID>
  </reference>
  <reference>
    <citation>Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, Hachem R, Wall M, Harris R, Jones J, Buzaid A, Robertson C, Shenaq S, Curling P, Burke T, Ericsson C. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med. 1997 Aug 15;127(4):267-74.</citation>
    <PMID>9265425</PMID>
  </reference>
  <reference>
    <citation>Rupp ME, Lisco SJ, Lipsett PA, Perl TM, Keating K, Civetta JM, Mermel LA, Lee D, Dellinger EP, Donahoe M, Giles D, Pfaller MA, Maki DG, Sherertz R. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial. Ann Intern Med. 2005 Oct 18;143(8):570-80.</citation>
    <PMID>16230723</PMID>
  </reference>
  <reference>
    <citation>Gong P, Li H, He X, et al. Preparation and antibacterial activity of Fe3O4@Ag nanoparticles. Nanotechnology 2007; 18: 604-11</citation>
  </reference>
  <reference>
    <citation>Shrivastava S, Bera T, Roy A, et al. Characterization of enhanced antibacterial effects of novel silver nanoparticles. Nanotechnology 2007; 18: 225103-225112</citation>
  </reference>
  <reference>
    <citation>Samuel U, Guggenbichler JP. Prevention of catheter-related infections: the potential of a new nano-silver impregnated catheter. Int J Antimicrob Agents. 2004 Mar;23 Suppl 1:S75-8.</citation>
    <PMID>15037331</PMID>
  </reference>
  <reference>
    <citation>Hsu SH, Tseng HJ, Lin YC. The biocompatibility and antibacterial properties of waterborne polyurethane-silver nanocomposites. Biomaterials. 2010 Sep;31(26):6796-808. doi: 10.1016/j.biomaterials.2010.05.015. Epub 2010 Jun 12.</citation>
    <PMID>20542329</PMID>
  </reference>
  <reference>
    <citation>Lai NM, Chaiyakunapruk N, Lai NA, O'Riordan E, Pau WS, Saint S. Catheter impregnation, coating or bonding for reducing central venous catheter-related infections in adults. Cochrane Database Syst Rev. 2013 Jun 6;(6):CD007878. doi: 10.1002/14651858.CD007878.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;3:CD007878.</citation>
    <PMID>23740696</PMID>
  </reference>
  <reference>
    <citation>Campisi C, Biffi R, Pittiruti M. Catheter-related venous thrombosis: the development of a nationwide consensus paper in Italy. J AssocVasc Access 2007; 12: 38-46</citation>
  </reference>
  <reference>
    <citation>Cortelezzi A, Moia M, Falanga A, Pogliani EM, Agnelli G, Bonizzoni E, Gussoni G, Barbui T, Mannucci PM; CATHEM Study Group. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol. 2005 Jun;129(6):811-7.</citation>
    <PMID>15953009</PMID>
  </reference>
  <reference>
    <citation>Kucher N. Clinical practice. Deep-vein thrombosis of the upper extremities. N Engl J Med. 2011 Mar 3;364(9):861-9. doi: 10.1056/NEJMcp1008740. Review.</citation>
    <PMID>21366477</PMID>
  </reference>
  <reference>
    <citation>Monreal M, Raventos A, Lerma R, Ruiz J, Lafoz E, Alastrue A, Llamazares JF. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines--a prospective study. Thromb Haemost. 1994 Oct;72(4):548-50.</citation>
    <PMID>7878630</PMID>
  </reference>
  <reference>
    <citation>Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e419S-e496S. doi: 10.1378/chest.11-2301. Erratum in: Chest. 2012 Dec;142(6):1698-1704.</citation>
    <PMID>22315268</PMID>
  </reference>
  <reference>
    <citation>Mehall JR, Saltzman DA, Jackson RJ, Smith SD. Fibrin sheath enhances central venous catheter infection. Crit Care Med. 2002 Apr;30(4):908-12.</citation>
    <PMID>11940768</PMID>
  </reference>
  <reference>
    <citation>Raad II, Luna M, Khalil SA, Costerton JW, Lam C, Bodey GP. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA. 1994 Apr 6;271(13):1014-6.</citation>
    <PMID>8139059</PMID>
  </reference>
  <reference>
    <citation>Pierce CM, Wade A, Mok Q. Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children. Intensive Care Med. 2000 Jul;26(7):967-72.</citation>
    <PMID>10990114</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2015</study_first_submitted>
  <study_first_submitted_qc>December 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2016</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Kang Yan</investigator_full_name>
    <investigator_title>professor; chief physician</investigator_title>
  </responsible_party>
  <keyword>central venous catheter (CVC)</keyword>
  <keyword>catheter-related bloodstream infection (CRBSI)</keyword>
  <keyword>catheter-related thrombosis (CRT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Catheter-Related Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

